Observational study to assess efficacy and safety of Bifidobacterium longumW11 plus Fructooligosaccharide combination in patients with irritable bowel syndrome (IBS) - NI

Abbott India Ltd0 个研究点目标入组 0 人开始时间: 待定最近更新: 2024年7月22日

试验速览

暂无简介。

•Patients of either sex, aged between 18 and 60 years
•OPD Patients with confirmed diagnosis of IBS with any of the three subtypes (viz IBS D/IBS C/IBS M)
•Patients with no improvement in symptoms despite treatment with antispasmodics

•Patients will be excluded if they have severe respiratory insufficiency organic brain damage sleep apnea syndrome severe acute or chronic
•hepatic insufficiency (risk of occurrence of encephalopathy) myasthenia gravis chronic psychosis major depressive episodes
•phobic or obsessional states or dementia
•Patients with other pre-existing GI disorders GI surgery abnormal upper and lower GI endoscopy finding family history of colon cancer or inflammatory bowel disease symptoms that discriminate lower GI organic diseases from IBS such as blood in stool nighttime symptoms
•that cause sleep disturbance unintentional weight loss or change in typical IBS symptoms such as new and/or different pain and alcohol or drug-dependency

发起方